Shinya Yamamoto

Shinya Yamamoto

Auto-generated profile, based on publicly available information

Shinya Yamamoto

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SYShinya Yamamoto
Shinya Yamamoto
MSMakoto Saito
Makoto Saito
ATAzumi Tamura
Azumi Tamura
DPDiki Prawisuda
Diki Prawisuda
TMTaketoshi Mizutani
Taketoshi Mizutani
HYHiroshi Yotsuyanagi
Hiroshi Yotsuyanagi
Background: Human microbiotas are communities of microorganisms living in symbiosis with humans. They play an important role in the host immune response to respiratory viral infection. However, evidence on the human microbiome and coronavirus disease (COVID-19) relationship is insufficient. The aim of this systematic literature review was to evaluate existing evidence on the association between the microbiome and COVID-19 in humans and summarize these data in the pandemic era. Methods: We conducted a systematic literature review on the association between the microbiome and COVID-19 in humans by searching PubMed, Embase, and the Cochrane Library, CINAHL, and Web of Science databases for articles in English published up to October 31, 2020. The results were analyzed qualitatively. This study is registered with PROSPERO (CRD42020195982). Results: Of the 543 articles identified by searching databases, 16 in line with the research objectives were eligible for qualitative review: eight sampled the microbiome using stool, four using nasopharyngeal or throat swab, three using bronchoalveolar lavage fluid, and one using lung tissue. Fecal microbiome dysbiosis and increased opportunistic pathogens were reported in COVID-19 patients. Several studies suggested the dysbiosis in the lung microbiome of COVID-19 patients with an abundance of opportunistic pathogens using lower respiratory tract samples. The association between COVID-19 severity and the human microbiome remains uncertain. Conclusion: The human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. Further research to elucidate the effect of alternation of the human microbiome in disease pathogenesis is warranted.

22 November 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
BKBrock Kingstad-Bakke
Brock Kingstad-Bakke
TCThomas Cleven
Thomas Cleven
HBHailey Bussan
Hailey Bussan
BYBoyd L. Yount
Boyd L. Yount
RURyuta Uraki
Ryuta Uraki
MSMarulasiddappa Suresh
Marulasiddappa Suresh
Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine–induced memory T cells limit lung SARS-CoV-2 replication and severe disease. We show that mice and humans receiving booster BioNTech mRNA vaccine developed potent CD8 T cell responses and showed similar kinetics of expansion and contraction of granzyme B/perforin-expressing effector CD8 T cells. Both monovalent and bivalent mRNA vaccines elicited strong expansion of a heterogeneous pool of terminal effectors and memory precursor effector CD8 T cells in spleen, inguinal and mediastinal lymph nodes, pulmonary vasculature, and most surprisingly in the airways, suggestive of systemic and regional surveillance. Furthermore, we document that: (a) CD8 T cell memory persists in multiple tissues for > 200 days; (b) following challenge with pathogenic SARS-CoV-2, circulating memory CD8 T cells rapidly extravasate to the lungs and promote expeditious viral clearance, by mechanisms that require CD4 T cell help; and (c) adoptively transferred splenic memory CD8 T cells traffic to the airways and promote lung SARS-CoV-2 clearance. These findings provide insights into the critical role of memory T cells in preventing severe lung disease following breakthrough infections with antibody-evasive SARS-CoV-2 variants.

10 May 2026 in Scientific Reports
Verified
Journal Article
Open access
SYShinya Yamamoto
Shinya Yamamoto
MKMakoto Kurano
Makoto Kurano
KOKoh Okamoto
Koh Okamoto
MKMasayuki Kubota
Masayuki Kubota
TTTakeya Tsutsumi
Takeya Tsutsumi
KMKyoji Moriya
Kyoji Moriya
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) is a heterogeneous multisystemic condition with unclear pathogenesis. Emerging evidence suggests that the disruption in metabolism, including lipid metabolism, can be involved in the pathogenesis of coronavirus disease 2019 (COVID-19). We previously measured the bioactive lipids in acute COVID-19, and we hypothesized that bioactive lipid dysregulation play a role in PASC pathogenesis. We conducted targeted LC-MS/MS analysis of sphingolipids and glycerophospholipids in serum samples from individuals with acute-phase COVID-19, including those who developed PASC, alongside healthy controls. We systematically examined lipidomic changes in serum samples, including analyses using linear mixed model, and found that no sphingolipid or glycerophospholipid species differed between the COVID-19 and PASC groups. Although these results are exploratory, the group x time interaction in the linear mixed model suggested that phosphatidylglycerol (PG) may represent a bioactive lipid distinguishing the COVID-19 and PASC groups. Given the small PASC sample size and that the signal was detected only at specific time points, these findings are hypothesis generating and should be confirmed in larger, adequately powered, and independently validated cohorts.

1 February 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SYShinya Yamamoto
Shinya Yamamoto
MIMahoko Ikeda
Mahoko Ikeda
YKYoshiaki Kanno
Yoshiaki Kanno
KOKoh Okamoto
Koh Okamoto
SOShu Okugawa
Shu Okugawa
KMKyoji Moriya
Kyoji Moriya

1 February 2018 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
SYShinya Yamamoto
Shinya Yamamoto
MIMahoko Ikeda
Mahoko Ikeda
FFFumie Fujimoto
Fumie Fujimoto
KOKoh Okamoto
Koh Okamoto
YWYoshitaka Wakabayashi
Yoshitaka Wakabayashi
KMKyoji Moriya
Kyoji Moriya

5 November 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
SYShinya Yamamoto
Shinya Yamamoto
KOKoh Okamoto
Koh Okamoto
HKHiraku Kumamaru
Hiraku Kumamaru
MSMakoto Saito
Makoto Saito
HIHiroshi Ito
Hiroshi Ito
KMKyoji Moriya
Kyoji Moriya
Ventricular assist device (VAD) infections are frequent causes of hospital readmission. The risk factors and optimal preventive strategies for such, including chronic suppressive antibiotics (CSA), remain uncertain. We performed a single-center, retrospective, observational cohort study assessing continuous flow VAD recipients who underwent implantation between 2008 and 2018 in Japan. From primary VAD infection (VADI), we followed the patients for recurrent infection, defined as relapsing VAD-specific (e.g., localized infections) or VAD-related (e.g., bacteremia) infections requiring hospital readmission. CSA was defined as the use of oral antimicrobial agents continued beyond initial antibiotic use until transplantation, VAD withdrawal, VADI recurrence, or death. Survival analysis was performed to identify risk factors for recurrent infection accounting for competing risks (e.g., deaths and transplants). Among 163 eligible patients, 76 patients had VADIs. The main causative organism in primary VADI was Staphylococcus aureus (63%, 48/76). Among them, 41 had recurrent infections, whereas 35 had none during the follow-up period (median, 335 days). Thirty-six patients received CSA for a median of 478 days. Although CSA was associated with a decreased risk of recurrent infection [adjusted sub-distribution hazard ratio (SHR), 0.40; 95% confidence interval (CI), 0.18–0.89; P = 0.03], this protective effect was observed only after primary VAD-specific infection (SHR, 0.28; 95% CI, 0.12–0.64; P < 0.01) but not after VAD-related infection. Surgical procedures during primary VADI were associated with an increased risk (SHR, 2.00; 95% CI, 1.10–3.66; P = 0.02). One patient had an adverse drug reaction. CSA may be an effective approach to limit relapsing VADIs following a primary VAD-specific infection with minimal adverse events. IMPORTANCE: Ventricular assist device infections (VADIs) are a significant complication leading to hospital readmissions. However, the risk factors and optimal preventive strategies for VADI remain unclear. This study investigated the effectiveness of chronic suppressive antibiotic therapy in patients with VADI. We found that the use of chronic suppressive antibiotic therapy was associated with a reduction in the risk of VADI recurrence with few adverse reactions. Our findings suggest the potential benefit of chronic suppressive antibiotics in preventing infections in selected cases. Our findings are relevant for the management of patients with ventricular assist devices awaiting heart transplantation, providing valuable insights for clinical practice.